Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Celgene
- Target Recruit Count
- 570
- Registration Number
- NCT02285062
- Locations
- 🇺🇸
Local Institution - 151, Dallas, Texas, United States
🇺🇸Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States
🇺🇸Local Institution - 161, Philadelphia, Pennsylvania, United States
Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2014-11-02
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 65
- Registration Number
- NCT02281084
- Locations
- 🇧🇪
Local Institution - 800, Liège, Belgium
🇵🇱Local Institution - 900, Warszawa, Poland
🇪🇸Local Institution - 300, Granada, Spain
Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q)
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 389
- Registration Number
- NCT02279654
- Locations
- 🇺🇸
Local Institution - 0002, Centre City, New Jersey, United States
🇺🇸Local Institution - France, No City Provided, New Jersey, United States
🇺🇸Local Institution - 0001, Centre City, New Jersey, United States
Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
- Conditions
- Interventions
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Celgene
- Target Recruit Count
- 21
- Registration Number
- NCT02273739
Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2018-12-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 36
- Registration Number
- NCT02269943
- Locations
- 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Columbia Comprehensive Cancer Care Clinic, Jefferson City, Missouri, United States
Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia
- Conditions
- Interventions
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1
- Registration Number
- NCT02267707
- Locations
- 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸Barbara Ann Karmanos Cancer Center, Detroit, Michigan, United States
🇩🇪St. Josef-Hospital, Bochum, Germany
Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Celgene
- Target Recruit Count
- 240
- Registration Number
- NCT02250326
- Locations
- 🇨🇦
Local Institution - 641, Montreal, Quebec, Canada
🇬🇧Local Institution - 636, Manchester, United Kingdom
🇮🇹Local Institution - 673, Bologna, Italy
Radiolabeled Study of CC-122 in Healthy Subjects
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 6
- Registration Number
- NCT02234999
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc, Madison, Wisconsin, United States
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
- First Posted Date
- 2014-08-22
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 89
- Registration Number
- NCT02223052
- Locations
- 🇺🇸
The Methodist Hospital Research Institute l, Houston, Texas, United States
🇺🇸Vanderbilt- Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
A Phase 2 Study With CC-220 in Skin Sarcoidosis
- Conditions
- Interventions
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Registration Number
- NCT02192489